The development of acquired resistance to osimertinib (Osim), an FDA‐approved third‐generation epidermal growth factor receptor (EGFR) inhibitor for the treatment of EGFR‐mutant nonsmall cell lung cancer, limits the long‐term benefits for patients. This evidence concerns the gene EGFR and lung cancer.